NH TherAguix's AGuIX Brain Metastases Trial Advances Following DSMB Validation
Key Insights
NH TherAguix (search) received DSMB validation to continue its Phase II NANOBRAINMETS trial evaluating AGuIX for brain metastases (search) treatment.
The trial assesses AGuIX plus stereotactic radiotherapy versus stereotactic radiotherapy alone, showing a favorable safety profile.
To date, 96 of the planned 134 patients have been randomized, with an interim efficacy analysis expected by year-end.
NH TherAguix (search) (NHT) has announced the Data Safety Monitoring Board (DSMB) has validated the continuation of its Phase II NANOBRAINMETS trial, which is evaluating AGuIX in treating patients with brain metastases (search). This decision follows a review of data from a futility analysis conducted after 50% of the trial's subjects were enrolled and followed up.
The randomized, double-blind trial, managed by the Dana Farber Cancer Institute, compares AGuIX plus stereotactic radiotherapy to stereotactic radiotherapy alone. The latest data indicates AGuIX has a favorable safety profile, with no serious adverse events reported. Currently, 96 out of the planned 134 patients have been randomized in the study. An interim analysis to assess clinical efficacy is anticipated by the end of this year.
AGuIX: Enhancing Tumor Targeting
AGuIX, developed by NHT, aims to improve tumor targeting and increase radiobiological damage to tumor tissues locally. This nanodrug contains a high concentration of gadolinium atoms within an ultrasmall structure. It is currently being evaluated in several Phase II randomized trials for various cancers, including brain metastases (search), glioblastoma (search), pancreatic cancer (search), and lung cancer (search). To date, over 200 patients have been treated with AGuIX, demonstrating a promising safety profile and encouraging preliminary clinical outcomes.
Future Outlook
NH TherAguix (search) CEO Vincent Carrère stated, "This first positive step paves the way for the major next inflexion point expected in the second half of the year regarding the interim efficacy analysis of AGuIX. The Phase II final results expected by Q2-Q3 2026 will be decisive for the further clinical development of AGuIX and its commercial approval for treating these cancers with high medical need."